Zymeworks Inc.
ZYMENASDAQHealthcare● Active
$23.83
$-0.21(-0.87%)
Market Cap$1.8B
P/E Ratio—
52W High$29.75
52W Low$11.51
Zymeworks Inc. (ZYME) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ZYME · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.59
Est. -$0.10 · -490.0%
Revenue
$0.00B
Est. $0.02B · -90.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ZYME reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.39 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.10 | -$0.59 | -490.0% | $0.00B | $0.02B | -90.1% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -$0.35 | -$0.55 | -57.1% | $0.00B | $0.02B | -86.9% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.30 | -$0.26 | +13.3% | $0.03B | $0.02B | +41.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.52 | $0.03 | +105.8% | $0.05B | $0.03B | +89.3% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.45 | -$0.30 | +33.3% | $0.03B | $0.02B | +50.4% |
| ▼ Q1 FY2025 | Mar 5, 2025 | $0.01 | -$0.31 | -3200.0% | $0.03B | $0.02B | +104.2% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.40 | -$0.39 | +2.5% | $0.02B | $0.05B | -66.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.59
EPS Est.
-$0.10
EPS Surpr.
-490.0%
Revenue
$0.00B
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
-$0.55
EPS Est.
-$0.35
EPS Surpr.
-57.1%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.3%
Revenue
$0.03B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.52
EPS Surpr.
+105.8%
Revenue
$0.05B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.45
EPS Surpr.
+33.3%
Revenue
$0.03B
Q1 FY2025
Mar 5, 2025Miss
EPS Actual
-$0.31
EPS Est.
$0.01
EPS Surpr.
-3200.0%
Revenue
$0.03B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.39
EPS Est.
-$0.40
EPS Surpr.
+2.5%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.13 | $-0.08 | $0.01 | 2 |
| Q3 FY2027 | $-0.09 | $0.52 | $0.81 | 2 |
| Q2 FY2027 | $-0.05 | $0.30 | $0.48 | 2 |
| Q1 FY2027 | $-0.23 | $-0.15 | $0.03 | 2 |
| Q4 FY2026 | $-0.04 | $0.25 | $0.38 | 4 |
| Q3 FY2026 | $0.03 | $2.20 | $2.94 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 3 |
| Q3 FY2027 | $0.0B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.0B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 4 |
| Q3 FY2026 | $0.0B | $0.2B | $0.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -490.0% | $27.61 | $26.60 | -3.66% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -57.1% | $23.29 | $23.31 | +0.09% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +13.3% | $18.05 | $17.90 | -0.83% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +105.8% | $12.41 | $12.16 | -2.01% |
| ▲ Q2 FY2025 | May 8, 2025 | +33.3% | $11.34 | $11.32 | -0.18% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -3200.0% | $12.75 | $13.18 | +3.37% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +2.5% | $13.87 | $13.70 | -1.23% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -17.4% | $10.46 | $10.11 | -3.35% |
Q2 FY2026-3.66%
Report Date
May 7, 2026
EPS Beat/Miss
-490.0%
Price Before
$27.61
Price After
$26.60
Q1 FY2026+0.09%
Report Date
Mar 2, 2026
EPS Beat/Miss
-57.1%
Price Before
$23.29
Price After
$23.31
Q4 FY2025-0.83%
Report Date
Nov 6, 2025
EPS Beat/Miss
+13.3%
Price Before
$18.05
Price After
$17.90
Q3 FY2025-2.01%
Report Date
Aug 7, 2025
EPS Beat/Miss
+105.8%
Price Before
$12.41
Price After
$12.16
Q2 FY2025-0.18%
Report Date
May 8, 2025
EPS Beat/Miss
+33.3%
Price Before
$11.34
Price After
$11.32
Q1 FY2025+3.37%
Report Date
Mar 5, 2025
EPS Beat/Miss
-3200.0%
Price Before
$12.75
Price After
$13.18
Q4 FY2024-1.23%
Report Date
Oct 31, 2024
EPS Beat/Miss
+2.5%
Price Before
$13.87
Price After
$13.70
Q3 FY2024-3.35%
Report Date
Aug 1, 2024
EPS Beat/Miss
-17.4%
Price Before
$10.46
Price After
$10.11
Avg Beat Reaction-1.06%
Avg Miss Reaction-0.89%
Beat Rate4 / 8 quarters
Largest Move-3.66% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ZYME ends December
Zymeworks Inc. (ZYME) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.59 — missing the analyst consensus of $-0.10 by -490.0%. The next ZYME earnings date is expected around September 1, 2026.
Each quarter, investors track ZYME earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ZYME revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ZYME's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ZYME earnings · 5 questionsZymeworks Inc.'s next earnings report is expected around September 1, 2026. ZYME typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ZYME historically reports after market close (AMC).
ZYME earnings datewhen is ZYME earningsZYME next earnings datewhen does ZYME report earningsZYME earnings calendar
▸ Source: FMP · Zymeworks Inc. SEC filings · US GAAP · Zymeworks Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026